Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545).
Gautschi
O
O
Zangemeister-Wittke
U
U
Stahel
R A
RA
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D019254:Genes, bcl-2 / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*; D013873:Thionucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; C408162:oblimersen; D017239:Paclitaxel